% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fuchs:307385,
      author       = {F. Fuchs and R. Herrera and R. Kotecha and M. Rubens and M.
                      Roy and K. E. Mittauer and S. Mansoorian and A. Kaiser and
                      N. Kalman and A. Gaasch and S. N. Marschner and N. Bassiri
                      and P. Rogowski and C. Eze and C. Belka$^*$ and S. Corradini
                      and M. D. Chuong},
      title        = {{M}ulti-{I}nstitutional {A}nalysis of {MR}-{G}uided
                      {S}ingle-{F}raction {S}tereotactic {A}blative {B}ody
                      {R}adiation {T}herapy: {F}easibility, {S}afety, and
                      {E}fficacy.},
      journal      = {International journal of radiation oncology, biology,
                      physics},
      volume       = {nn},
      issn         = {0360-3016},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2025-03029},
      pages        = {nn},
      year         = {2025},
      note         = {epub / Autoren checken},
      abstract     = {Stereotactic ablative body radiation therapy (SABR) is
                      commonly delivered in multiple fractions, whereas
                      single-fraction (SF) SABR remains uncommon. Magnetic
                      resonance (MR) guided linacs provide superior soft-tissue
                      contrast compared to cone-beam computed tomography on
                      conventional linacs, online adaptive replanning, continuous
                      intrafraction visualization, and automatically triggered
                      beam delivery, potentially enabling safe and effective
                      SF-SABR.We retrospectively analyzed patients treated with
                      MR-guided SF-SABR on a 0.35 Tesla MR-linac at two centers in
                      XXX and XXX (anonymized for review). Median SF-SABR doses
                      were 28 Gy (range: 28-40 Gy) for liver lesions, 30 Gy
                      (range: 28-34 Gy) for lung lesions, 25 Gy for adrenal gland
                      lesions and lymph nodes, and 26 Gy (range: 25-26 Gy) for
                      renal lesions. Endpoints included local control (LC),
                      progression-free survival (PFS), overall survival (OS), and
                      toxicity graded according to CTCAE v5.0.Between April 2020
                      and December 2024, 161 patients with 175 lesions underwent
                      MR-guided SF-SABR. Lesion distribution was liver $(48.0\%),$
                      lung $(42.9\%),$ adrenal gland $(4.3\%),$ lymph nodes
                      $(3.4\%),$ and kidney $(1.9\%).$ Median gross tumor volume
                      (GTV) and planning target volume were 2.4 cc (range:
                      0.2-83.3 cc) and 9.3 cc (range: 1.4-112.1 cc), respectively.
                      At a median follow-up of 19.3 months, LC rates at 1 and 2
                      years were $99.1\%$ and $93.6\%,$ respectively. PFS rates at
                      1 and 2 years were $59.3\%$ and $51.4\%,$ while OS rates
                      were $81.8\%$ and $73.4\%,$ respectively. Treatment was well
                      tolerated, with only one acute grade 3 toxicity reported and
                      no acute grade 4-5 or late grade 3-5 toxicities. Colorectal
                      primary tumors were associated with poorer LC (HR 0.226;
                      p=0.023). Larger GTV independently correlated with reduced
                      LC (HR 1.15; p=0.048) and OS (HR 1.05; p=0.001).MR-guided
                      SF-SABR is feasible, safe, and effective across various
                      tumor locations, providing favorable LC with minimal
                      toxicity, warranting further prospective evaluation.},
      cin          = {MU01},
      ddc          = {610},
      cid          = {I:(DE-He78)MU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41422918},
      doi          = {10.1016/j.ijrobp.2025.12.018},
      url          = {https://inrepo02.dkfz.de/record/307385},
}